Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Insight Molecular Diagnostics Inc. (IMDX) had Return on Tangible Equity of 40.13% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.03M |
|
$-4.29M |
|
$0.02M |
|
$0.01M |
|
$4.45M |
|
$-4.41M |
|
$0.12M |
|
$-4.29M |
|
$-4.29M |
|
$-4.29M |
|
$-4.29M |
|
$-4.29M |
|
$-4.29M |
|
$-4.41M |
|
$-3.78M |
|
34.52M |
|
34.52M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$30.52M |
|
$8.91M |
|
$9.91M |
|
$40.43M |
|
$12.01M |
|
-- |
|
$39.11M |
|
$51.12M |
|
$-10.69M |
|
$-10.69M |
|
$-10.69M |
|
32.29M |
|
| Cash Flow Statement Financials | |
$-7.64M |
|
$-0.61M |
|
$24.70M |
|
$12.92M |
|
$29.36M |
|
$16.44M |
|
$0.61M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.54 |
|
-- |
|
-- |
|
-- |
|
-0.16 |
|
46.88% |
|
-13790.62% |
|
-13790.62% |
|
-- |
|
-13406.25% |
|
-13406.25% |
|
$-8.25M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
0.04 |
|
0.20 |
|
441.56 |
|
40.13% |
|
|
Return on Tangible Equity |
40.13% |
-10.61% |
|
40.13% |
|
$-0.33 |
|
$-0.24 |
|
$-0.22 |
|